Tandem Therapeutics

Description

Tandem Therapeutics develops Matrix Targeting Peptides that bind disease-associated extracellular matrix alterations, applying extracellular matrix biology research to precision approaches for fibrosis, organ fibrosis, and fibrotic cancers.

Tandem Therapeutics is located in the Zurich ecosystem.

Related

• AcytronixAcytronix provides PMED, a portable microstructured electrochemical device that rapidly isolates extracellular vesicles from biofluids…
• Agomab TherapeuticsAgomab Therapeutics develops disease-modifying therapies for fibro-inflammatory conditions through TGFβ/ALK5 (TGFβR1) pathway targeting,…
• Lattice MEDICALLattice MEDICAL develops tissue-engineering and 3D-printed resorbable implants for soft-tissue regeneration, including a 3D-printed…
• Molecular PartnersMolecular Partners develops DARPin therapeutics, including Radio-DARPins and logic-gated Switch-DARPins, to target DLL3, FAP x CD40, and…
• Enterprise TherapeuticsEnterprise Therapeutics researches and develops respiratory disease therapies, including inhaled ENaC blocker ETD001, to address mucus…
• Prevision MedicinePrevision Medicine tests living cancer and healthy cells from a patient biopsy against 100+ drugs and combinations using a patented ex vivo…
• GratXrayGratXray develops breast cancer imaging technology, including senoa breast CT, combining scientific work with safer, more reliable,…
• EnzyTagEnzyTag develops peptiligase-based synthetic routes for manufacturing peptide new chemical entities, small proteins, and peptide…
• Devyser DiagnosticsDevyser Diagnostics develops DNA test kits and integrated software for laboratory DNA diagnostics, helping labs run genetic testing…